This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Towards the end of 2015, I wrote about growing recognition of the importance of the microbiome for human health and consequently for commercial biopharmaceutical development here. Still microbiome research […]
March 22, 2016 Comments Off on Which pharmaceutical companies have the most “New Dosage Form” drugs? Posted in: General Biotechnology 
New Dosage Forms are one of the categories for which the FDA grants three years of exclusivity for ‘New Clinical Investigations.’ Alternate categories worth of three years of protection include identifying a New Patient Population, New Product, or New Strength. This chart shows the companies which have received the most New Dosage Form exclusivities in […]